Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Immunogenicity and Safety of EV71 Vaccine in Pediatric Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy children aged from 3 to 6 years old (i.e. ≥ 3 years old and \< 7 years old) for Part A,and from 2 to 35 months old (i.e. ≥ 2 months old and \< 36 months old) for Part B at the time of first vaccination.~2. Subject's guardians are able and willing to comply with study procedures and provide the signed informed consent.~3. Subject is able and can comply with the requirements of the protocol.~4. Subject with body temperature ≤38°C.~Exclusion Criteria:~1. Subject with previous known exposure to Enterovirus 71 (EV71).~2. Subject with a history of herpangina, hand-foot-mouth disease,and acute hemorrhagic conjunctivitis associated with enterovirus infection in the past 3 months.~3. Subject with gestation \< 37 weeks.~4. Subject with birth weight \<2.5 kg.~5. Subject with a history of hypersensitivity to vaccines, or a history of allergic disease or reactions likely to be exacerbated by any component of the vaccine.~6. Family history of seizures or progressive neurological disease.~7. Family history of congenital or hereditary immunodeficiency.~8. Severe malnutrition or dysgenopathy.~9. Major congenital defects or serious chronic illness, including perinatal brain damage.~10. Subject diagnosed of having autoimmune disease (e.g., celiac disease, type I diabetes, lupus (SLE), juvenile dermatomyositis, scleroderma, juvenile idiopathic arthritis (JIA), immune (or idiopathic) thrombocytopenia purpura).~11. Bleeding disorder diagnosed by a doctor or significant bruising or hemostatic difficulties with IM injections or blood draws.~12. Any acute infections 7 days prior to administrating the first vaccination.~13. Use of any investigational product (including drug, vaccine) within 30 days prior to vaccination or planned use during the study period.~14. Administration of any vaccines within 14 days prior to randomization.~15. Use of immunoglobulins or any blood products within 3 months prior to vaccination or planned use during the study period.~16. Chronic administration (defined as \> 14 days) of immunosuppressants or other immunomodulators or systemic corticosteroids within 6 months prior to vaccination or planned use during the study period.~17. Subjects who had ever received investigational EV-71 vaccine prior to randomization.~18. Under anti-tuberculosis prevention or therapy.~19. Any condition that in the opinion of the investigator may interfere with the evaluation of study objectives.

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 6 Years
- Healthy Volunteers: t

Study Arms:
- Group A1 (Type: EXPERIMENTAL): 3 to 6 years
- Group A2 (Type: EXPERIMENTAL): 3 to 6 years
- Group A3 (Type: EXPERIMENTAL): 3 to 6 years
- Group B1 (Type: EXPERIMENTAL): 2 to 35 months
- Group B2 (Type: EXPERIMENTAL): 2 to 35 months
- Group B3 (Type: EXPERIMENTAL): 2 to 35 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete